New depression drug shows early promise in small safety study
NCT ID NCT06965569
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This early-stage study tested a new medicine called ALA-3000 in 37 adults whose depression did not get better with standard treatments. The main goal was to see if the drug is safe and how the body processes it. Researchers also looked for early signs that it might help lift depression symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT DEPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arch Clinical Trials
St Louis, Missouri, 63141, United States
-
Clinilabs Drug Development Corporation
Eatontown, New Jersey, 07724, United States
-
Neuro-Behavioral Clinical Research, Inc
North Canton, Ohio, 44720, United States
-
Pillar Clinical Research
Little Rock, Arkansas, 72204, United States
Conditions
Explore the condition pages connected to this study.